Floatz logo

Deucrictibant

Hereditary Angioedema Type II

Pharvaris Netherlands B.V.Small moleculePhase 3Active
BBB
73/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
62/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Hereditary Angioedema Type II cohort.

Asset / SponsorPhaseRating
Adx-324
ADARx Pharmaceuticals, Inc.
Phase 3B

Same molecule, other indications

Deucrictibant is also rated in:

hereditary angioedema with C1Inh deficiencyDormant
BBB
Indicative ·
78 / 100
View asset →
C1 Esterase Inhibitor DeficiencyDormant
BBB
Indicative ·
78 / 100
View asset →
C1 Inhibitor DeficiencyDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →